Compare OBIO & ACV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBIO | ACV |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 272.8M |
| IPO Year | 2020 | N/A |
| Metric | OBIO | ACV |
|---|---|---|
| Price | $5.43 | $26.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.25 | N/A |
| AVG Volume (30 Days) | ★ 274.5K | 34.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.20% |
| EPS Growth | ★ 33.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | N/A |
| 52 Week Low | $2.20 | $22.30 |
| 52 Week High | $5.78 | $29.04 |
| Indicator | OBIO | ACV |
|---|---|---|
| Relative Strength Index (RSI) | 75.80 | 41.30 |
| Support Level | $4.07 | $25.75 |
| Resistance Level | N/A | $26.80 |
| Average True Range (ATR) | 0.29 | 0.57 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 82.11 | 11.19 |
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.